Find support throughout your treatment journey
With TeamingUp for Diabetes, you can get help managing your condition with a dedicated team of Coaches and Champions. Sign up today for useful information, recipes, tools, and more—all delivered right to your inbox.
Please provide your information below.
*Required fields
What is Admelog® (insulin lispro injection) 100 Units/mL?
Prescription Admelog is a fast-acting human insulin used to improve blood sugar control in adults with Type 2 diabetes and adults and children (3 years and older) with Type 1 diabetes.
Important Safety Information
Do not use Admelog if you have low blood sugar or if you are allergic to insulin lispro or any of the other ingredients in Admelog.
Do not share needles, insulin pens, or syringes with others, even if the needle is changed. Do NOT reuse needles. You may give other people a serious infection, or get a serious infection from them.
Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting pitted or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.
Before starting Admelog, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed.
Heart failure can occur if you are taking insulin together with pills called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Admelog. Your treatment with TZDs and Admelog may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms, including:
- Shortness of breath
- Sudden weight gain
- Swelling of your ankles or feet
Tell your doctor about all the medications you take, including OTC medicines, vitamins, supplements, and herbal supplements.
When used as a mealtime insulin, Admelog should be taken within 15 minutes before a meal or immediately after a meal. Test your blood sugar levels as directed by your doctor when using Admelog. Do not change your dose or type of insulin without talking to your doctor. Any change of insulin should be made cautiously and only under medical supervision.
Check your insulin label to verify that you have the correct insulin before each injection. Admelog must only be used if the solution is clear and colorless with no particles visible.
While using Admelog, do not drive or operate heavy machinery until you know how Admelog affects you. Do not drink alcohol or use medicines that contain alcohol.
Admelog may cause serious side effects that can lead to death, including:
- Low blood sugar (hypoglycemia). Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood changes, hunger.
- Serious allergic reactions. Get medical help right away if you have: a rash over your whole body, trouble breathing, fast heartbeat, feeling faint, or sweating.
- Low potassium in your blood (hypokalemia). Your doctor should monitor you for low blood potassium levels.
- Heart failure. Your doctor should monitor you closely while you are taking TZDs with Admelog.
Get emergency medical help if you have:
- Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.
Admelog may have additional side effects including injection site reactions which may include change in fat tissue, skin thickening, redness, swelling and itching.
Important Safety Information for Admelog® (insulin lispro injection) SoloStar®
Admelog SoloStar is a disposable single-patient-use prefilled insulin pen. Talk to your doctor about proper injection technique and follow instructions in the Instruction Leaflet that comes with the pen.
Important Safety Information for Admelog (insulin lispro injection) when used in a pump
Do not mix or dilute Admelog when used in a pump.
Failure of your insulin pump or infusion set or degradation of the insulin in the pump can cause hyperglycemia and ketoacidosis. Always carry an alternate form of insulin administration in the case of pump failure.
Click here for Full Prescribing Information for Admelog.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
©2024. Sanofi. All rights reserved. Admelog is a registered trademark of Sanofi or an affiliate.
All registered trademarks cited are property of their respective owners.
These are not all the possible side effects of Admelog. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.
Indications and Usage for Apidra
Prescription Apidra is a fast (rapid) acting insulin used for adults and children with diabetes mellitus to control high blood sugar. It is not known if APIDRA is safe or effective in children less than 4 years of age with type 1 diabetes or in children with type 2 diabetes.
When used as a mealtime insulin, Apidra should be given within 15 minutes before or within 20 minutes after starting a meal.
Apidra may be infused subcutaneously by external insulin infusion pumps.
Important Safety Information
Do not use Apidra if you have low blood sugar reaction or if you are allergic to insulin glulisine or any of the ingredients in Apidra.
Do not share needles, insulin pens or syringes with others even if the needle is changed. Do NOT reuse needles. You may give other people a serious infection or get a serious infection from them.
Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting lipodystrophy (pitted or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.
Before starting Apidra, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed.
Heart failure can occur if you are taking insulin together with pills called TZDs (thiazolidinediones), even if you never had heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Apidra. Your treatment with TZDs and Apidra may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have new or worsening symptoms, including:
- Shortness of breath
- Sudden weight gain
- Swelling of your ankles or feet
Tell your doctor about all medications you take, including OTC medicines, vitamins, supplements, and herbal supplements.
When used a mealtime insulin, Apidra should be taken within 15 minutes before a meal or within 20 minutes after starting a meal. Test your blood sugar levels as directed by your doctor when using Apidra. Do not change your dose or type of insulin without talking to your doctor. Any change of insulin should be made cautiously and only under medical supervision.
Check your insulin label to verify that you have the correct insulin before each injection. Use Apidra only if the solution is clear and colorless with no particles visible.
While using Apidra, do not drive or operate heavy machinery until you know how Apidra affects you. Do not drink alcohol or use medicines that contain alcohol.
Apidra may cause serious side effects that can lead to death, including:
- Low blood sugar (hypoglycemia). Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood changes, hunger.
- Serious allergic reactions. Get medical help right away if you have: a rash over your whole body, shortness of breath, trouble breathing, fast pulse, sweating or feeling faint
- Low potassium in your blood (hypokalemia). Your doctor should monitor you for low blood potassium levels.
- Heart failure. Your doctor should monitor you closely while you are taking TZDs with Apidra.
Get emergency medical help if you have:
- Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.
The most common side effects of APIDRA include: low blood sugar (hypoglycemia), weight gain, itching, rash, swelling, allergic reactions including injection site reactions, skin thickening or pits at the injection site (lipodystrophy).
Important Safety Information for Apidra® (insulin glulisine injection) SoloStar®
Apidra SoloSTAR is a disposable single-patient-use prefilled insulin pen. Please talk to your healthcare provider about proper injection techniques and follow instructions in the Instruction Leaflet that accompanies the pen.
Important Safety Information for Apidra® when used in a pump
Replace the infusion sets (reservoir, tubing, and catheter), and the Apidra in the reservoir at least every 48 hours and select a new infusion site. Do not mix or dilute Apidra when used in the pump. Failure of your insulin pump or infusion set or degradation of the insulin in the pump can cause hyperglycemia and ketoacidosis. Always carry an alternate form of insulin administration in the case of pump failure.
Click here for Full Prescribing Information for Apidra.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
©2024. Sanofi. All rights reserved. Apidra is a registered trademark of Sanofi or an affiliate.
If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610.
The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.
What is Lantus® (insulin glargine injection) 100 Units/mL?
Prescription LANTUS is a long-acting man-made-insulin used to control high blood sugar in adults and children with diabetes mellitus.
- LANTUS is not for use to treat diabetic ketoacidosis
Important Safety Information
Do not take Lantus during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus.
Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles.
Before starting Lantus, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed.
Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting lipodystrophy (pitted or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.
Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus. Your treatment with TZDs and Lantus may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including:
- Shortness of breath
- Swelling of your ankles or feet
- Sudden weight gain
Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, including herbal supplements.
Lantus should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.
Do NOT dilute or mix Lantus with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection.
While using Lantus, do not drive or operate heavy machinery until you know how Lantus affects you. You should not drink alcohol or use other medicines that contain alcohol.
The most common side effect of insulin, including Lantus, is low blood sugar (hypoglycemia), which may be serious and life threatening. It may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision.
Lantus may cause serious side effects that can lead to death, such as severe allergic reactions. Get medical help right away if you have:
- A rash over your whole body
- Trouble breathing
- A fast heartbeat
- Sweating
- Swelling of your face, tongue, or throat
- Shortness of breath
- Extreme drowsiness, dizziness, or confusion
Other possible side effects may include swelling, weight gain, low potassium levels, injection site reactions, including changes in fat tissue at the injection site, and allergic reactions.
Important Safety Information for Lantus (insulin glargine injection) SoloStar
Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.
Click here for Full Prescribing Information for Lantus.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
©2024. Sanofi. All rights reserved. Lantus is a registered trademark of Sanofi or an affiliate.
SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, which may improve blood sugar (glucose) control in adults with type 2 diabetes when used with diet and exercise.
- It has not been studied in people with a history of pancreatitis.
- It is not recommended for people who also take lixisenatide or other medicines called GLP-1 receptor agonists.
- It is not for use in people with type 1 diabetes, or people with diabetic ketoacidosis.
- It has not been studied in people who have a stomach problem that causes slow emptying (gastroparesis) and is not for people with slow emptying of the stomach.
- It has not been studied in people who also take a short-acting (prandial) insulin.
- It is not known if SOLIQUA 100/33 is safe and effective in children under 18 years of age.
Important Safety Information for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL
What is the most important information I should know about SOLIQUA 100/33?
Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be severe and lead to death.
Before using SOLIQUA 100/33, tell your doctor if you have had pancreatitis, stones in your gallbladder (cholelithiasis), or a history of alcoholism. These medical problems may make you more likely to get pancreatitis.
Stop taking SOLIQUA 100/33 and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.
Who should not use SOLIQUA 100/33?
Do not use SOLIQUA 100/33 if you:
- are having an episode of low blood sugar (hypoglycemia)
- are allergic to insulin glargine, lixisenatide, or any of the ingredients in SOLIQUA 100/33. Symptoms of a severe allergic reaction with SOLIQUA 100/33 may include swelling of the face, lips, tongue, or throat, fainting or feeling dizzy, problems breathing or swallowing, very rapid heartbeat, severe rash or itching, or low blood pressure.
Who should not use SOLIQUA 100/33?
Do not use SOLIQUA 100/33 if you:
- are having an episode of low blood sugar (hypoglycemia)
- are allergic to insulin glargine, lixisenatide, or any of the ingredients in SOLIQUA 100/33. Symptoms of a severe allergic reaction with SOLIQUA 100/33 may include swelling of the face, lips, tongue, or throat, fainting or feeling dizzy, problems breathing or swallowing, very rapid heartbeat, severe rash or itching, or low blood pressure.
Before using SOLIQUA 100/33, tell your healthcare provider about all your medical conditions, including if you:
- have or have had problems with your pancreas, your kidneys, or your liver, stones in your gallbladder, or a history of alcoholism.
- have heart failure or other heart problems. If you have heart failure, it may get worse while you take thiazolidinediones (TZDs).
- have severe problems with your stomach, such as slowed emptying of your stomach or problems digesting food.
- are taking certain medicines called glucagon-like peptide 1 receptor agonists (GLP-1 receptor agonists).
- have had an allergic reaction to a GLP-1 receptor agonist.
- are pregnant or breastfeeding or plan to become pregnant or to breastfeed. It is not known if SOLIQUA 100/33 will harm your unborn baby or pass into your breast milk.
Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements. SOLIQUA 100/33 may affect the way some medicines work. Before using SOLIQUA 100/33, talk to your healthcare provider about low blood sugar and how to manage it.
How should I use SOLIQUA 100/33?
- Do not change your dose without first talking to your healthcare provider.
- Check the pen label each time you inject to make sure you are using the correct medicine.
- Do not take more than 60 units of SOLIQUA 100/33 each day. Do not take SOLIQUA 100/33 with other GLP-1 receptor agonists.
- Only use SOLIQUA 100/33 that is clear and colorless to almost colorless. If you see small particles, return it to your pharmacy for replacement.
- Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting pitted or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.
- Do not remove SOLIQUA 100/33 from the pen with a syringe.
- Do not re-use or share needles with other people. You may give other people a serious infection, or get a serious infection from them.
- Check your blood sugar levels. Ask your healthcare provider what your blood sugar should be and when you should check.
What are the possible side effects of SOLIQUA 100/33?
SOLIQUA 100/33 can cause serious side effects including:
- See "What is the most important information I should know about SOLIQUA 100/33?"
- Severe allergic reactions. Severe allergic reactions can happen with SOLIQUA 100/33. Stop taking SOLIQUA 100/33 and get medical help right away if you have any symptoms of a severe allergic reaction. See "Who should not use SOLIQUA 100/33?"
- Low blood sugar (hypoglycemia). Your risk for getting low blood sugar is higher if you take another medicine that can cause low blood sugar. Signs and symptoms of low blood sugar include:
- headaches
- weakness
- fast heartbeat
- dizziness
- irritability
- feeling jittery
- drowsiness
- hunger
- confusion
- sweating
- blurred vision
- anxiety
- Kidney problems (kidney failure). In people who have kidney problems, the occurrence of diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse.
- Low potassium in your blood (hypokalemia).
- Heart failure. Taking certain diabetes pills called TZDs with SOLIQUA 100/33 may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with SOLIQUA 100/33. Your healthcare provider should monitor you closely while you are taking TZDs with SOLIQUA 100/33. Tell your healthcare provider if you have any new or worse symptoms of heart failure including shortness of breath, swelling of your ankles or feet, or sudden weight gain. Treatment with TZDs and SOLIQUA 100/33 may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure.
- Gallbladder problems. Gallbladder problems have happened in some people who take SOLIQUA 100/33. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include:
- pain in your upper stomach (abdomen)
- fever
- yellowing of skin or eyes (jaundice)
- clay-colored stools
The most common side effects of SOLIQUA 100/33 include:
- low blood sugar (hypoglycemia)
- nausea
- stuffy or runny nose and sore throat
- diarrhea
- upper respiratory tract infection
- headache
Nausea and diarrhea usually happen more often when you first start using SOLIQUA 100/33.
These are not all the possible side effects of SOLIQUA 100/33. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Click here for full Prescribing Information for SOLIQUA 100/33.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.
©2024. Sanofi. All rights reserved. Soliqua is a registered trademark of Sanofi or an affiliate.
Indication
Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus. Limitations of Use: Toujeo is not recommended for the treatment of diabetic ketoacidosis.
Important Safety Information for Toujeo U-300 (insulin glargine) injection
Do not use Toujeo if you have low blood sugar or if you are allergic to insulin or any of the ingredients in Toujeo.
Do not share your pen(s) with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Before starting Toujeo, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant, or if you are breastfeeding or planning to breastfeed.
Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting pitted or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred, or damaged.
Heart failure can occur if you are taking insulin together with pills called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Toujeo. Your treatment with TZDs and Toujeo may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms including:
- Shortness of breath
- Sudden weight gain
- Swelling of your ankles or feet
Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, and herbal supplements.
Toujeo should be taken at the same time once a day. Test your blood sugar levels daily while using any insulin. Do not change your dose or type of insulin without talking to your doctor. Verify you have the correct insulin before each injection. Do NOT use a syringe to remove Toujeo from your pen. Your dose for Toujeo may be different from other insulins you have taken. Any change of insulin should be made cautiously and only under medical supervision.
Do NOT dilute or mix Toujeo with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Use Toujeo only if the solution is clear and colorless with no particles visible.
While using Toujeo, do not drive or operate heavy machinery until you know how Toujeo affects you. Don’t drink alcohol or use other medicines that contain alcohol.
The most common side effect of Toujeo is low blood sugar (hypoglycemia), which may be serious and life-threatening. Severe hypoglycemia may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision. The long-acting effect of Toujeo may delay recovery from low blood sugar compared to shorter-acting insulins.
Toujeo may cause severe allergic reactions that can lead to death. Get medical help right away if you have:
- A rash over your whole body
- Shortness of breath
- Swelling of your face, tongue, or throat
- Extreme drowsiness, dizziness, or confusion
- Trouble breathing
- Fast heartbeat
- Sweating
Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching.
Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. It is important to perform a safety test when using a new pen for the first time. Talk to your doctor about proper injection technique and follow instructions in the Instruction Leaflet that comes with your Toujeo SoloStar or Toujeo Max SoloStar pen.
Click here for full Prescribing Information for Toujeo U-300.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.
©2024. Sanofi. All rights reserved. Toujeo is a registered trademark of Sanofi or an affiliate.